Stock Taper 
| DATE | TYPE | RATIO |
|---|---|---|
| 2019-03-26 | Reverse | 1:5 |
CorMedix Inc. develops and commercializes therapies like DefenCath/Neutrolin to prevent infections and thrombosis related to central venous catheters in clinical settings worldwide.
DefenCath® is the first FDA-approved antimicrobial catheter lock solution, containing taurolidine and heparin, designed to reduce bloodstream infections in adult hemodialysis patients with central venous catheters, and is CorMedix’s primary commer...
In a pivotal move for the company, CorMedix completed its acquisition of Melinta Therapeutics in August 2025. This strategic acquisition diversified CorMedix from a single-product entity to a multi-product commercial operation, significantly broadening its portfolio of anti-infective treatments and setting the stage for substantial revenue growth.
In a move that fundamentally reshapes its business, CorMedix completed the acquisition of Melinta Therapeutics, evolving from a single-product entity to a multi-product commercial operation. This acquisition significantly broadens CorMedix's portfolio with the addition of seven marketed anti-infective products, establishing a strong presence in the acute and life-threatening illness market.
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both CorMedix (CRMD) and Prothena (PRTA). But which of these two stocks offers value investors a better bang for their buck right now?
Overall rating: B+
| PEER | PRICE | |
|---|---|---|
 TNGX | $21.55 | COMPARE |
 PVLA | $129.97 | COMPARE |
 SEPN | $35.95 | COMPARE |
 NBTX | $25.02 | COMPARE |
 BCAX | $16.61 | COMPARE |
 SVRA | $4.66 | COMPARE |
 KURA | $10.56 | COMPARE |
 ABUS | $4.45 | COMPARE |
